Newly-Listed Sionna Therapeutics Touts Positive Data From Lung Disease Candidate In Healthy Volunteer Trial

Why did Tesla shares plunge recently? How are Trump tariffs impacting global trade? What caused Procter & Gamble's recent job cuts? Why is the Trump-Musk feud affecting markets? How is Circle's IPO influencing crypto markets? Why did ECB cut interest rates again? What is behind Lululemon's profit forecast downgrade?

Newly-Listed Sionna Therapeutics Touts Positive Data From Lung Disease Candidate In Healthy Volunteer Trial

benzinga.com/news/health-care/25/06/45778064/newly-listed-sionna-therapeutics-touts-positive-data-from-lung-disease-candidate-in-healthy-volu

Sionna Therapeutics, Inc. (NASDAQ:SION) released data from its Phase 1 trials of SION-719 and SION-451, the company’s first-in-class nucleotide-binding domain 1 (NBD1) stabilizers, in healthy volunteers.
One hundred subjects were dosed in the SION-719 trial, and 110 subjects were dosed…

This story appeared on benzinga.com, 2025-06-04 17:54:01.